University of Cincinnati Department of Pediatrics

Philip Walson, MD

Appointment

Professor

Email

p.walson@chmcc.org

Phone

513-636-5872

Fax

513-636-8453

Bio

Philip D. Walson, MD, was born in Brooklyn, N.Y., but grew up in Los Angeles, Calif. He received his BS in Chemistry with honors from the University of California, Berkeley, in 1965, and his MD from the University of California, San Francisco, in 1969.

Dr. Walson brings many years of experience in clinical trials. For nearly two decades before coming to Cincinnati Children's, he was Professor of Pediatrics, Pharmacology and Pharmacy at The Ohio State University and Chief of Clinical Pharmacology/Toxicology and Medical Director of the TDM/Toxicology Laboratory, which he started, at Children's Hospital in Columbus. He was also principal investigator of the NICHD (National Institutute of Child Health and Human Development) supported Pediatric Pharmacology Research Unit (PPRU) and the NIMH (National Institute of Mental Health) supported Research Unit of Pediatric Psychopharmacology (RUPP) in Columbus.

Dr. Walson is the author of more than 100 publications. He is a member of the American Academy of Pediatrics' Committee on Drugs and the USP Nomenclature Committee. He was co-founder, Medical Director and Chief Scientific Officer of Pediatric Clinical Trials International, a subsidiary of Children's Hospital, Columbus, dedicated to development of pediatric therapeutics. Dr. Walson is board certified in pediatrics, clinical pharmacology, and medical toxicology. He is editor of Current Therapeutics, past editor of Current Therapeutic Research, and past president of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.

Credentials

MD: University of California, San Francisco, Calif., 1969.

Residency: Pediatrics, University of Chicago, Chicago, Ill.

Fellowship: Clinical Pharmacology, CVRI/Dept of Internal Medicine, University of California, San Francisco, Calif.

Certifications: Pediatrics, 1976 and 1983 (voluntary recertification) Medical Toxicology, 1978, (independent board); 1994 (Pediatric Sub-Board); Clinical Pharmacology, 1991.

Awards and Honors

National Institutes of Health (NIH) Fogarty Senior International Fellowship, 1979-80. Japan Society for the Promotion of Science Fellowship June 1993.
Elected member Society for Pediatric research, the American Pediatric Society, and the American Board of Medical Toxicology.
Elected member 1985-1990 and chair of the U.S. Pharmacopeia (USP) Pediatric Panel, 1990-95 and 1995-2000. USP Honor Citation, 1999.
United States Pharmacopeial DID Fellowship Selection Committee 1993
Elected Vice President, International Association of Therapeutic Drug Monitoring and Clinical Toxicology 5/93-9/95
Japan Society for the Promotion of Science Fellowship 6/1-6/21/93
Invited speaker, 35th Annual Meeting of the Japanese Society of Child Neurology 6/17/93
Visiting Professor, Beijing Medical University, China 5/20/94
Invited speaker, FDA Nonprescription Drugs Advisory Committee (NDAC) and OTC Analgesic Subcommittee of the FDA Arthritis Advisory Committee 9/8-9/94
Invited faculty participant, "Pharmacokinetics and Pharmacodynamics in Adolescents", National Institute of Child Health and Development, Bethesda, Maryland 1/20-21/94
Invited Speaker and Organizing Committee member, 5th World Congress of the World Federation of Associations of Clinical Toxicology Centers & Poison Control Centers 11/8-11/94
Visiting Professor, University of Hawaii/Chubu Hospital, Okinawa, Japan 11/14-18/94
Elected President, International Association of Therapeutic Drug Monitoring and Clinical Toxicology 9/95-11/97
Consultant in Pediatrics, University of Hawaii Post-graduate Medical Education Program for Okinawa Prefecture 2/5-9/96
Elected member, 1995-2000 USP Committee of Revision 1995-2000
Elected to Chair the 1995-2000 USP DID Pediatrics Expert Advisory Panel 1995-2000
Invited speaker, American Association of Clinical Chemistry Course: Professional Practice in Toxicology: A Review, Cincinnati, Ohio 6/23-26/96
Chair, USP Open Conference on "Children and Medicines: Information Isn't Just for Grownups", Reston, Virginia 9/29-10/1/9
Elected Full Member, American College of Medical Toxicology 9/96
Fellow, American College of Clinical Pharmacology 2/4/97
Inducted into the Bulgarian National Academy of Medicine 5/8/97
Appointed Member, Committee on Drugs, American Academy of Pediatrics 7/97-6/99
Invited participant, Advances in Clinical and Forensic Toxicity, IV Indianapolis Indiana. Sponsored by Midwest Association for Toxicity and Therapeutic Drug Monitoring and Department of Pathology and Laboratory Medicine 4/24-25/97
Invited participant, American Academy of Pediatrics, AM:PREP review course: Pharmacology and Toxicology, Atlanta, GA 9/14-18/97
Invited participant, Daiichi Pharmaceutical Corporation Speakers Bureau 9/97-Present
Consultant in Pediatrics, University of Hawaii Post-graduate Medical Education Program for Okinawa Prefecture 12/14-19/97
Elected Member, Section on Clinical Pharmacology & Therapeutics Executive Committee, American Academy of Pediatrics 10/97-Present
Outstanding Speaker Award, American Association for Clinical Chemistry, Inc. 1997
Recipient, Paul Harris Fellow Award, Rotary Club of Columbus 2/23/98
Invited participant, Efficacy and Safety of Paracetamol as an OTC Drug Symposium, Ministry of Health of Russian Federation, National Institute for Pre-clinical and Clinical Drug Evaluation, State Pharmacological Committee, Moscow, Russia 9/23/98
Appointed Member, Work Group on Medication Compliance, American 3/1/99-Present
Academy of Pediatrics, Re-appointed for 2000
US Pharmacopeia Honor Citation for long-term contributions to USP 4/99
Elected Member, USP Pediatric Expert Panel 2000-2005 Revision Cycle 9/00
Elected 2000-2005 USP Expert Committee on Nomenclature and Labeling (USP NLC) 7/00-05
Certificate of Service, Health Volunteers Overseas, St Lucia 12/00
Invited speaker, IIR Pediatric Conference, Industry Experience in Paediatric Clinical Trials, London 1/24-25/01
Invited speaker, NCPIE's 13th Annual National Conference "Educate Before You Medicate: A Prescription for Safety, Bethesda, MD 5/16-18/01
Invited participant, Duragesic (Janssen Research Foundation/Quintiles) FEN-USA-87 Investigators' Meeting, San Diego, CA 5/01
Invited speaker, Pharmacia-Upjohn Linezolid DSMB Meeting, Kalamazoo, MI 7/10/01
Invited participant, FEB-USA-87 World Meeting, Lisbon Portugal 7/01
Invited participant, 23rd International Congress of Pediatrics, Beijing,China 9/9-14/01
Elected member, Planning Committee for International Child Health, CCHMC 3/2002
Selected for inclusion in "Guide to America's Pediatricians" 2002-2003 Consumer Guide, Consumer's Research Council of America, Washington, DC 5/2002

Research

Pediatric clinical pharmacology/toxicology and clinical trials methodology; therapeutic drug monitoring -- especially of anti-epileptic drugs; pediatric hypertension.

Research Grants and Contracts

Corporate/Anonymous Trial # PR99-11-034
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Weekly P. . . . . " (E. . . . . A. . . . .) on Anemia and Quality of Life in Children with Malignant Solid Tumors or Hodgkin's Disease Undergoing Myelosuppressive Chemotherapy.
08/Aug/00 -

Corporate/Anonymous Trial #PR99-11-044
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Weekly P. . . . .  (E. . . . . A. . . . .) on Anemia and Quality of Life in Children with Acute Lymphocytic Leukemia (ALL) or Non-Hodgkin's Lymphoma Undergoing Myelosuppressive Chemotherapy.
14/Sept/00 -

Corporate/Anonymous Trial # RP59500V-324
Open-Label, Multicenter, Multiple-Dose, Phase III Study of the Population Pharmacokinetics of IV S. . . . . (7.5 mg/kg, Q8H) in 75 Pediatric Patients.
12/Dec/00 -

Corporate/Anonymous Trial #LOFBO- PHI-115
An Open Label Single Dose Study To evaluate The Safety and Pharmacokinetics of L. . . . . Oral Suspension Formulation in Infants and Children (6 months to 16 years of age)
29/May/01-

Corporate/Anonymous Trial #S1330074 A Pharmacokinetic and Safety Study of Four N. . . . . Replacement Therapy Formulations In Adolescent Smokers.
04/Aug/00

Corporate/Anonymous Trial# CEF-98-025
Pharmacokinetics of Cefditoren in Infants and Children Following a Single Oral Dose of C. . . . . P. . . . ..
30/Nov/01 – 08/May/01

Corporate/Anonymous Trial # WP16296/A
Single-dose Pharmacokinetics and Tolerability of i.v. G. . . . . and Oral V. . . . . r Syrup Formulation in Pediatric Renal Transplant Recipients
20/Mar/01 -

Corporate/Anonymous Trial # SD-004-0732
Safety and Efficacy Study of Two Dosage-Levels of P. . . . . R. . . . . (Budesonide Inhalation Suspension, 0.5 or 1.0 mg/day) versus Placebo in Infants Between the Ages of Six and Twelve Months with Mild to Moderate Asthma
29/Aug/00

Corporate/Anonymous Trial #C-2000-042-01
The Safety and tolerability of O. . . . . Chloride (D……… XL", D………. " Syrup or D…….." Tablets) in the Treatment of Detrusor Hyperreflexia due to Neurogenic Conditions in Children Aged 6 to 15 Years.
Aug/00 -

Corporate/Anonymous Trial #S1330074
A Pharmacokinetic and Safety Study of Four N. . . . . Replacement Therapy Formulations In Adolescent Smokers.
04/Aug/00

Corporate/Anonymous Trial# CEF-98-025
Pharmacokinetics of C . . . . .. in Infants and Children Following a Single Oral Dose of C. . . . . P. . . . ..
30/Nov/01 – 08/May/01

Corporate/Anonymous Trial #AQ-00-04
A Single-Dose, Randomized, Open-Label, Multicenter, Parallel Group, Confirmatory Pharmacokinetic Study Of Children's A. . . . Cold & Sinus Suspension In 2 To 6 Year-Old Children
06/Jul/01 – 29/Mar/01

Corporate/Anonymous Trial # AR-00-03
A Bioavailability Study of a Suspension formulation of combination OTC products in Children 6 to <12 yrs of age with Symptoms consistent with Allergic Rhinitis.
24/Apr/02- 16/Dec/02

Corporate/Anonymous Trial # 9008A1
A multicenter, Prospective, Randomized, Double-blind, Parallel Trial to Assess Safety, Tolerance and Change in Fecal Bacteria in Healthy Toddlers Consuming a Nutritional Product in combination
May/2002

Corporate/Anonymous Trial # 155-01
An Open-labeled Study to Investigate the Pharmacokinetic Profile of a Bisphosphonate in Glucocorticoid Treated Pediatric Patients.
Aug/2002

Agency for Healthcare Research and Quality (AHRQ) –Subcontract with University of North Carolina Center
for Education and Research in Therapeutics (CERT)
Pharmacokinetics and Pharmacodynamics of HIV Drugs
9/30/02– 9/29/07*

Corporate/Anonymous Trial # 25213-097
A Multicenter, Randomized, Comparative study to evaluate the Efficacy and Safety of a Fluoroquinolone in the Treatment of Children who have recurrent and/or persistent acute Otitis Media
Oct/2002

Corporate/Anonymous Trial # LTSS-001
A Multicenter, Long-Term, Active-Surveillance Study of Musculoskeletal Disorders that occur after initiating a course of Fluoroquinolone or Non-Fluoroquinolone Therapy for Acute Infectious Diseases in Children who were enrolled in Phase 3 Clinical Quinolone Trial.
Oct/2002

Publications, Most Recent

Journal Articles

Lohani SP, Walson PD, Ekins BR, Wananukul W. Amphetamine poisoning case report. Access 1(4):3, 1998.

Casavant M, Walson P, Wolowich W, Kelley M. Near fatal ingestion of household lamp oil – Ohio, August 1997. MMWR 47(41):880-882, 1998.

Bush PJ, Ozias JM, Walson PD, Ward RM. Ten guiding principles for teaching children and adolescents about medicines. Clin Ther 1(7):1280-1284, 1999.

Boni JP, Korth-Bradley JM, Martin P, Simcoe DK, Richards LS, Rennebohm R, Walson PD. Pharmacokinetics of Etodolac in patients with stable juvenile rheumatoid arthritis. Clin Ther 21(10):1715-24, 1999.

Walson, PD. Patient Recruitment: US Perspective. Pediatrics 104(3): 619-22, 1999

McDougle CJ, Scahill L, McCracken JT, Aman MG et al. Research Units on Pediatric Psychopharmacology (RUPP)- Autism network: Background and rationale for an initial controlled study of risperidone. Child and Adolescent Psychiatric Clinics of North America 9(1):201-224, 2000.

Prober, CG, Walson PD, and Jones, J. American Academy of Pediatrics Technical Report: Precautions Regarding the Use of Aerosolized Antibiotics, Pediatr 2000; 106(6):e89

Marshall, J, Rodarte A, Blumer J, Khoo K-C, Akbari B, Kearns G, and the Pediatric Pharmacology and the Research Unit Network. Pediatric Pharmacodynamics of Midzaolam Oral Syrup. J Clin Pharmacol, 2001; 40:578-589

James, LP, Farrar HC, Sullivan, JE, Givens, TG, Kearns, GL, Wasserman, GS, Walson, PD, Hinson, JA, Pumford, NR, and the Pediatric Pharmacology Research Unit Network, NICHD- Measurement of Acetaminophen-Protein Adducts in Children and Adolescents with Acetaminophen OverdosesJ Clin Pharmacol, 2001; 41(8) 846-851

Chesney, RW, Adamson, P, Wells, T, Wilson, JT, and Walson, PD. The Testing of Antihypertensive Medications in Children: Report of the Antihypertensive Agent Guidelines Subcommittee of the Pediatric Pharmacology Research Units, Pediatrics 2001;107:558-561

Wells, T, Rippley, R, Hogg R, Sakarcan, A, Blowey, D, Walson P, et al.. The Pharmacokinetics of Enalapril in Children and Infants with Hypertension. J Clin Pharmacol, 2001; 41:1064-75

Pierce, CH, Walson PD: Therapeutic Orphans are Losing Their Guardians or Where are the Trained Pediatric Investigators. GCPJ Aug 2002.

Blumer, JL, Daniels SR, Blaney S, Walson PD, Roman D, and Ouellet D.: Pharmacokinetics of Quinapril in Children: Assessment During Substitution for Chronic Angiotensin-Converting Enzyme Inhibitor Treatment. J Clin Pharmacol 2003:43:128-132.

Textbook Chapters

Bressler R, Walson PD. Drug absorption, distribution, metabolism, and excretion. Mead Johnson Symp.Peri.Dev.Med. 5:1974.

Walson PD. Absorption and distribution of antibiotics in the developing child. Mead Johnson Symp.Peri.Dev.Med. 5:1974.

Walson PD, Bressler R. Drugs and age. In: Drugs of choice (76 77 ed), edited by Modell W, Saint Louis, The C.V. Mosby Company, 1976:30 42.

Walson PD. Special Treatment Services Pharmacy. In: Hospital Care of Children and Youth, edited by Committee on Hospital Care, Evanston, American Academy of Pediatrics, 1978:51 52.

Walson PD, Bressler R. Drugs and age. (revised). In: Drugs of choice (78 79 ed), edited by Modell, W. Saint Louis, The C.V. Mosby Company, 1978:31 47.

Walson PD. Bioavailability a clinician's viewpoint. In: Principles and perspectives in drug bioavailability, Karger Press, 1979:274 289.

Mimaki T, Walson PD. Vitamin D metabolism in rats: evidence of different mechanism for phenytoin and phenobarbital. In: Advances epileptology, edited by Canger and Penry, Raven Press, 1980.

Walson PD, Bressler R. Drugs and age (revised). In: Drugs of choice (80 81 ed), edited by Modell, W. Saint Louis, The C.V. Mosby Company, 1980:21 39.

Walson PD, Powell JR, Mimaki T. Anticonvulsant usage. In: Pediatric pharmacology, edited by Yaffe S, Grune & Stratton, 1980:195 212.

Walson PD, Bressler R, Fulginiti VA. The routine use of hexachlorophene (HCP) in the newborn nursery should be banned. In: Current controversies in therapeutics, edited by Lasagna, L. W.B. Saunders, 1980:419 426.

Walson PD, Bressler R. Drugs and age (revised). In: Drugs of choice (82 83 ed), edited by Modell, W. Saint Louis: The C.V. Mosby Company, 1982:21 40.

Walson PD. Giving medicine to children. In: Pediatric consult, 1984.

Braden NJ, Jackson JE, Walson PD. Tricyclic antidepressant overdose. In: Pediatric clinics of north america, 1986:287 297.

Walson PD, Edwards R, Cox S. Neonatal therapeutic drug monitoring its clinical relevance. In: Neonatal Therapy: An update, edited by Rubaltelli, F.F. and Granati, B. Elsevier Science Publishers B.V., 1986:289 296.

Walson PD. Clinical pharmacology. In: Community management of children and youth with emotional disturbance and mental retardation: a curriculum for advanced training, edited by Hammer, D. and Mulick, J. 1989:42 47.

Edge J, Walson PD. Clonazepam and 7 aminoclonazepam in human plasma. In: Recent developments in therapeutic drug monitoring and clinical toxicology, edited by Sunshine, I. New York: Marcel Dekker, Inc., 1992:321 324.

Mimaki T, Walson PD, Suzuki Y. Anticonvulsants. In: Pediatric pharmacology therapeutic principles in practice, edited by Yaffe, S.J. and Aranda, J.V., W.B. Saunders Co., 1992:287 302.

Walson PD. Practical aspects of neonatal therapeutic drug monitoring. In: Recent developments in therapeutic drug monitoring and clinical toxicology, edited by Sunshine, I., Marcel Dekker, New York, 1992:65 70.

Walson PD. Fever. In: Conn's Current Therapy 1997, edited by Rakel, Robert E, W. B. Saunders Company, Philadelphia, 1997:23-27.

Walson PD. Paediatric clinical pharmacology and therapeutics. In: Avery's Drug Treatment, 4td ed, edited by Speight TM and Holford NHG, Adis International, Auckland, New Zealand, 1997:127-171.

Walson PD, Casavant M. Lidocaine. In: Clinical Management of Poisoning and Drug Overdose, 3rd ed, edited by Haddad LM, Shannon MW, Winchester JF, W. B. Saunders Company, Philadelphia, 1998:1064-1069.

McDougle CJ, Scahill L, Walson, PD et al. Research Units on Pediatric Psychopharmacology (RUPP)
Autism Network: Background and rationale for an initial controlled study of Risperidone. In: Child and Adolescent Psychiatric Clinics of North America, edited by Lewis M, Martin A, Scahill L. W.B. Saunders Company, Philadelphia, 2000:9(1):201-224.

Walson, PD. Toxicokinetics: Principles and Practical Applications, Chapter 2 in Toxicology, American
Academy of Clinical Chemistry Press, Washington DC, 2001:15-21.

Vinks, AA, Walson PD. Pharmacokinetics I: Developmental Principles. In: Martin A, Scahill L, Charney D, Leckman J, editors. Pediatric Psychopharmacology: Principles and Practice. New York: Oxford University Press; 2003. p. 44-53.

Editorials

Walson PD. Editorial Comment. Clin Ther 21(1): 1, 1999.

Walson PD. Editorial Comment. Clin Ther 21(2): 279, 1999.

Walson PD. Editorial Comment. Clin Ther 21(3): 431, 1999.

Walson PD. Editorial Comment. Clin Ther 21(4): 613, 1999.

Walson PD. Editorial Comment. Clin Ther 21(5): 789, 1999.

Walson PD. Editorial Comment. Clin Ther 21(6): 931, 1999.

Walson PD. Editorial Comment. Clin Ther 21(7):1117, 1999.

Walson PD. Editorial Comment. Clin Ther 21(8): 1285, 1999.

Walson PD. Editorial Comment. Clin Ther 21(9): 1427, 1999

Walson PD. Editorial Comment. Clin Ther 21(10): 1631, 1999.

Walson PD. Editorial Comment. Clin Ther 21(11): 1821, 1999.

Walson PD. Editorial Comment. Clin Ther 21(12): 2037, 1999.

Walson PD. Editorial Comment. Clin Ther 22(1): 1, 2000.

Walson PD. Editorial Comment. Clin Ther 22(2): 153, 2000.

Walson PD. Editorial Comment. Clin Ther 22(3): 265, 2000.

Walson PD. Editorial Comment. Clin Ther 22(4): 371, 2000.

Walson PD. Editorial Comment. Clin Ther 22(5): 499, 2000.

Walson PD. Editorial Comment. Clin Ther 22(6): 653, 2000.

Walson PD. Editorial Comment Clin Ther 22(7): 797, 2000.

Walson PD. Editorial Comment Clin Ther 22(8): 897, 2000.

Walson PD. Editorial Comment. Clin Ther 22(9): 1003, 2000.

Walson PD. Editorial Comment. Clin Ther 22(10): 1149, 2000.

Walson PD. Editorial Comment. Clin Ther 22(11): 1253, 2000.

Walson PD. Editorial Comment. Clin Ther 22(12): 1377, 2000.

Walson PD. Editorial Comment. J Pediatr Pharmacol Ther 6:97-9, 2001.

Walson PD. Editorial Comment. Clin Ther 23(1): 1, 2001

Walson PD. Editorial Comment. Clin Ther 23(3): 311, 2001

Walson PD. Editorial Comment. Clin Ther 23(4): 519, 2001

Walson PD. Editorial Comment. Clin Ther 23(5): 645, 2001

Walson PD. Editorial Comment. Clin Ther 23(6): 771, 2001

Walson PD. Editorial Comment. Clin Ther 23(8): 1129, 2001

Walson PD. Editorial Comment. Clin Ther 23(9): 1321, 2001

Professional Organization Memberships

American Association for the Advancement of Science

American Academy of Pediatrics, Central Ohio Chapter

American Academy of Pediatrics, Section of Clinical Pharmacology and Therapeutics

American Federation of Clinical Research

American Society for Clinical Pharmacology and Therapeutics

Central Ohio Pediatric Society

Western Society for Pediatric Research

Society for Pediatric Research

American Academy of Clinical Toxicology

American Academy of Clinical Toxicology, Acute and Intensive Care Section

Midwest Society for Pediatric Research

American Board of Medical Toxicology

American Pediatric Society

Medical Symposium Group, Columbus, Ohio

International Association of Therapeutic Drug Monitoring and Clinical Toxicology

American Academy of Pharmaceutical Physicians

Alpha Epsilon Chapter of Phi Beta Delta Honor Society for International Scholars

Special Interests

International health and travel.Editing

Editor, Clinical Therapeutics; editorial board member; Therapeutic Drug Monitoring (U.S. and Japanese journals); Current Therapeutic Research.

Presentations

Antiepileptic drug monitoring in pediatric patients. (Oral presentation). Sixth Meeting of the Balkan Clinical Laboratory Federation, Oct. 8-11, 1998, Plovdiv, Bulgaria. (See Walson, P.; Balkan, J.; <i>Clin Lab</i>, 2:30, 1998).

Toxicokinetics: Principles and Practical Applications, American Association for Clinical Chemistry, Contemporary Practice in Clinical Toxicology Course, June 9, 2000, Alexandria, Va.

Effective Provider Education Programs to Improve Antibiotic Use. Ninth International Congress on Infectious Diseases, April 13, 2000, Buenos Aires, Argentina. (See abstract 94.002, page 207 of abstracts.)

Software

Investigator on project which developed a CD-ROM for children with leukemia; to explain their disease and clinical trials developed. Done under contract to Degge Group, which markets the CD.